Abstract | Patients with chronic kidney disease (CKD) are at increased risk of atherosclerotic cardiovascular disease and loss of renal parenchyma accelerates atherosclerosis in animal models. Macrophages are central to atherogenesis because they regulate cholesterol traffic and inflammation in the arterial wall. CKD influences macrophage behavior at multiple levels, rendering them proatherogenic. Even at normal creatinine levels, macrophages from uninephrectomized Apoe -/-mice are enriched in cholesterol owing to downregulation of cholesterol transporter ATP-binding cassette subfamily A member 1 levels and activation of nuclear factor κB, which leads to impaired cholesterol efflux. Interestingly, treatment with an angiotensin-II-receptor blocker (ARB) improves these effects. Moreover, atherosclerotic aortas from Apoe -/-mice transplanted into renal-ablated normocholesterolemic recipients show plaque progression and increased macrophage content instead of the substantial regression seen in recipient mice with intact kidneys. ARBs reduce atherosclerosis development in mice with partial renal ablation. These results, combined with the clinical benefits of angiotensin-converting-enzyme (ACE) inhibitors and ARBs in patients with CKD, suggest an important role for the angiotensin system in the enhanced susceptibility to atherosclerosis seen across the spectrum of CKD. The role of macrophages could explain why these therapies may be effective in end-stage renal disease, one of the few conditions in which statins show no clinical benefit.
Introduction more than 50% of deaths in patients with chronic kidney disease (CKD) on dialysis are attributable to cardio vascular disease. 1 even modest renal dysfunction, includ ing isolated albuminuria, results in a dramatic increase in the risk of cardiovascular disease. [2] [3] [4] [5] the relationship between decreasing renal function and increasing rates of cardiovascular disease and mortality is due to multiple mechanisms, including abnormal myocardial remodel ing, ventricular hypertrophy, arrhythmia and cardiac arrest; the influence of these factors depends on the level of CKD. Compared with the prevalence of athero sclerotic disease in individuals with intact kidney func tion, however, atherosclerotic disease is over represented across the entire spectrum of patients with CKD. macrophages have critical roles in all stages of athero sclerotic lesion formation and mounting experimental evidence implicates their importance in the vascular complications of renal disease. macrophages contribute to all stages of athero sclerosis through their role in inflammation and lipid homeo stasis. 6 retention of atherogenic lipoproteins in the arterial intima prompts the production of leukocyte chemo attractant molecules. these molecules activate receptors on rolling monocytes, which leads to their initial adhe sion mediated by selectins, followed by their integrin dependent adhesion to the endothelium and their subsequent diapedesis into the intima. 7 Chemokines (chemotactic cytokines) and their receptors have been implicated in the migration of monocytes and t cells into the arterial intima. 8 the critical role for macrophages in the development of atherosclerosis is illustrated by the observation that osteopetrotic mice, which lack macro phage colonystimulating factor, have low numbers of macrophages in their atherosclerotic lesions and a small lesion area, even in the presence of severe hyper lipidemia. 9 macrophages also have a central role in innate immunity. 10 the interaction between antigenpresenting dendritic cells and t cells activates the adaptive immune response and defines the inflammatory processes of early atherogenesis. ligation of CD40 on activated t cells leads to enhanced production of t helper (t H ) 1 cell cytokines, including interferon γ, 11 which is proatherogenic. 12 this t H 1 cytokine cascade is counterbalanced by the presence of antiatherogenic t H 2 cytokines, including interleukin (il)10. 13 this review focuses on the mechanisms of CKDinduced atherosclerosis, with particular empha sis on the role of macrophages, as demonstrated by experimental studies and data from clinical studies.
Macrophages and atherosclerosis
the accumulation of macrophages laden with chole sterol ester in the arterial intima is the hallmark of fatty streak formation in humans and experimental models. macrophages internalize atherogenic lipoproteins (such as oxidized lDl) via scavenger receptors, including www.nature.com/nrneph CD36 14 and class a scavenger receptors (sra). 15, 16 native lipoprotein receptors, such as the lDl receptor related protein 1, 17 are also expressed by macrophages and contribute to atherogenesis. Cholesterol entry into macrophages is counterbalanced by the efflux of free chole sterol into acceptor particles (such as HDl). 18 Free cholesterol efflux is mediated by active trans porters, such as atPbinding cassette sub family a member 1 (aBCa1), atPbinding cassette subfamily G member 1 (aBCG1) and scavenger receptor class B member i (srBi), or by passive diffusion. 19 an in vitro study of isolated mouse macrophages demonstrated that abca1 mediates the efflux of free cholesterol and phospholipids to both apo lipoprotein a1 (apoa1) and apolipoprotein e (apoe). 20 apoe is abundantly expressed by macrophages in athero sclerotic lesions, 21 might represent the physiological acceptor of cholesterol in atherosclerotic plaques, 20 and 23 macrophages also influence atherogenesis through their susceptibility to death. endoplasmic reticulum stress is a major inducer of macrophage apoptosis 24, 25 and, whereas macrophage apoptosis in the early stages of atherogenesis might result in reduced lesion cell ularity, 26 apoptosis in advanced lesions expands the necrotic core owing to impaired phagocytosis of apop totic bodies. 27 In vitro and in vivo experiments from our laboratory revealed a critical cooperative role for lDl receptorrelated protein 1 and apoe in a functional axis that regulates efferocytosis of apoptotic macrophages in atherosclerotic lesions. 28 
CKD modulates macrophage function
Macrophage infiltration anatomical and radiological analyses document that CKD dramatically accelerates growth of atherosclerotic lesions. [29] [30] [31] [32] atherosclerotic plaques of patients with CKD are more complex than those of individuals with normal renal function, and have features that suggest greater instability. these features include increased lipid content, widespread necrosis, disruption of the extracellular matrix, and enhanced inflammation. 30 macrophages, the largest cell contingent of the atheroma, are involved in all of these processes.
experimental studies in atherosclerosisprone Apoe -/-mice reveal that a reduction in the renal parenchyma, ranging from uninephrectomy to subtotal renal ablation, significantly expands macrophagepositive areas within the intima (Figure 1 ). [33] [34] [35] Peritoneal macrophages har vested from uninephrectomized Apoe -/-mice show 50% greater migratory activity in response to chemo attraction with CCchemokine ligand (CCl) 2 (also known as monocyte chemoattractant protein 1) than macrophages obtained from Apoe -/-mice with intact kidneys. 35 experimental renal ablation activates numerous vascular chemotactic cytokines and chemokine receptors, includ ing vascular cell adhesion molecule 1 (vCam1), inter cellular cell adhesion molecule 1 (iCam1), eselectin, il6, tumor necrosis factor and CCl2, to promote macro phage adhesion to the endothelium and trans migration into the subendothelial space. [36] [37] [38] increased vascular expression of some of these factors precedes both the elevation in their plasma levels and the development of arterial plaques in renalablated Apoe -/-mice, findings that support a role for early macrophage recruitment into the vessel wall in renalinjuryinduced atherogenesis. 34 Plasma levels of adhesion molecules and markers of inflammation and oxidation are increased in patients with CKD and correlate with the degree of renal impair ment.
39-43 indeed, high plasma levels of iCam1 and Figure 1 | Potential pathways by which CKD modulates the accumulation of arterial macrophages. CKD potentiates macrophage infiltration into the vessel wall by increasing the expression of vascular adhesion molecules (VCAM1, ICAM1 and selectins) and chemoattractants (CCL2 and MCSF). CKD modifies extracellular matrix components of the vasculature (for example, the oxidation or glycation of glycoproteins, collagen, and elastin), thereby increasing lipoprotein retention and the migratory capacity of macrophages. CKD impairment of macrophage egress from the vessel wall might involve disruption of the CCR7 pathway. Abbreviations: CCL2, CC-chemokine ligand 2; CCR7, CC-chemokine receptor 7; CKD, chronic kidney disease; ICAM1, intercellular adhesion molecule 1; MCSF, macrophage colony-stimulating factor; VCAM1, vascular cell adhesion molecule 1. reViewS vCam1 are strong independent predictors of poor outcome in patients with CKD.
43 uremic serum increases the expression and shedding of adhesion mol ecules by vascular endothelial cells. 44 the coronary plaques of patients with CKD (particularly calcified plaques) have increased expression of the inflammatory markers CD40-CD154 and of Creactive protein. 45 notably, peripheral leukocytes of patients with CKD have greater responses to inflammatory and oxidative stimuli than those of healthy controls.
46-48 even without stimulation, circulating granulocytes and monocytes of patients on dialysis produce elevated levels of super oxide and hydro gen peroxide, and have greater expression of CD11b/ CD18 integrins than those of healthy indivi duals. 47 in addition, monocytes from patients with endstage renal disease (esrD) have suppressed levels of anti inflammatory cytokines and seem to be more susceptible to macrophage transformation than cells from normal controls. 46 such observations support the idea that CKD increases systemic inflammation, vascular micro inflammation and macrophage priming, all of which can amplify the expression of cytokines by macrophages and their recruitment into the subendothelial space.
a major contributor to heightened inflammation is the enhanced oxidative stress that develops early in CKD, persists as renal function declines, and is not improved by dialysis treatment. [47] [48] [49] [50] [51] [52] urea, at disease relevant concentra tions, stimulates the generation of reactive oxygen species in vitro and in vivo. 53 Factors that promote oxidative stress in the setting of CKD include naDPH oxidase, uncoupled endothelial nitric oxide synthase and myeloperoxidase. 49, 54, 55 myeloperoxidase is a predictor of cardiovascular disease risk and is abundantly expressed by neutrophils and macrophages within athero sclerotic lesions in patients with CKD. 56, 57 Compared with healthy controls, leukocyte lysate from patients with CKD has increased myeloperoxidase activity, which is not improved by dialysis.
46 a single nucleotide poly morphism in the promoter region of the myelo peroxidase gene has been associated with reduced expression of myelo peroxidase and linked to reduced prevalence of cardio vascular disease in patients with CKD and esrD. 58, 59 treatments that decrease oxidative stress and inflammation, such as Nacetylcysteine or neutraliz ing antibodies against the receptor for advanced glycation end products, significantly reduce experimental athero sclerosis caused by renal dysfunction. 60, 61 moreover, and in contrast with results in the general population, anti oxidative therapy substantially reduces cardio vascular morbidity in patients with CKD. 62, 63 For example, Nacetylcysteine has been shown to decrease concen trations of oxidized lDl cholesterol by 76% and the composite end points of nonfatal myocardial infarction, cardiovascular death, revasculariza tion and ischemic stroke by 40% in patients with stage 5 CKD. 62, 63 in these same small studies, antioxidant therapy with vitamin e reduced the rate of cardiovascular end points by >50% and the rate of myocardial infarction by 70% in patients on hemodialysis. 62, 63 although antioxidant therapies decrease levels of electronegative lDl and biomarkers of oxidative stress in patients with mild to moderate CKD and patients with esrD on hemo dialysis, [64] [65] [66] no large clinical trials have been conducted to evaluate the effi cacy of such interventions on the risk of cardiovascular events or death in these populations. indeed, largescale, longterm followup studies of vitamin e supplementa tion in individuals with normal renal function have been disappointing. 67, 68 nonetheless, CKD increases oxidative stress, thus creating an optimal set up for antioxidant therapies to target macrophage infiltration and function. However, currently available antioxidant therapies might not be sufficiently effective to influence the complexi ties that underlie the increased mortality rates in patients with CKD.
Macrophage egress in addition to increased cellular infiltration, the vascular accumulation of macrophages in CKD might be caused by their increased survival or decreased egress from the vascular wall ( Figure 1 ). transplantation of athero sclerotic aorta from hyperlipidemic Apoe -/-mice into normolipemic wildtype mice results in plaque regres sion and the loss of foam cells into the local lymphatic system and circulation. 23, 69, 70 substantial foamcell exit is observed within 3 days of transplantation. the resolu tion of the atheroma under these conditions also includes abatement in areas of necrosis, extracellular accumulation of cholesterol, and fibrosis. 71 in a 2010 study, renal abla tion has been shown to inhibit macrophage emigration out of the vessel wall. 72 transplantation of atheromatous aortic segments from Apoe -/-mice into normolipemic mice after renal ablation did not cause plaque regres sion as seen after transplantation of atheromatous aortic segments from Apoe -/-mice into normolipemic recipient mice with intact kidneys. on the contrary, the plaques of renalablated normolipemic recipients actually expanded and contained more macrophages than those of recipi ents with intact kidneys. the increased macrophage content was not linked to changes in cellular survival and macrophages within the plaques of renalablated mice showed downregulation of serum response factor target genes and upregulation of the migration factor CCr7. in view of the dynamic nature of the atherosclerotic plaque, impaired plaque regression and decreased macrophage emigration in the setting of renal damage might contrib ute not only to accelerated atherosclerosis, but also to the lack of vascular benefits from treatments that lower plasma lipids in advanced CKD.
Macrophage trapping
CKDinduced changes within the local vascular milieu and modulation of macrophage function may cause sub endothelial trapping of macrophages ( Figure 1) . CKD increases the oxidation and glycosylation of matrix mol ecules including proteoglycans, collagen, and elastin. 73, 74 modifications of extracellular matrix promote lipoprotein retention and oxidation and lead to increased cholesterol accumulation by the macrophage, resulting in increased cholesterol content in the cellular membrane, which causes stiffness and impaired cellular mobility. 75 ,76 reViewS macrophage migration and trapping are also affected by the scavenger receptor CD36, which is upregulated in monocytes of patients with CKD and uremia. 77, 78 one study showed that CD36mediated uptake of oxidized lDl induced actin polymerization and cell spreading via activation of focal adhesion kinase and inactivation of src homology 2containing phosphotyrosine phosphatase, which inhibited cellular migration. 79 other investiga tors, however, have reported that upregulation of CD36 actually enhances macrophage migration.
80,81 since CD36 regulates several specific intracellular signaling pathways related not only to cellular migration but also to inflamma tion and cholesterol efflux, CD36 activation might induce several diverse functions depending on the activating trigger in each particular biological setting. 82 CKD and macrophage lipid homeostasis macrophage foamcell formation results from an imbalance between lipoprotein uptake and cholesterol efflux (Figure 2) . scavenger receptors are upregulated in macro phages from patients with CKD as well as in tissues such as the aorta and kidneys of animals with renal injury. 77, 78, [83] [84] [85] [86] monocytes from patients on hemo dialysis or peritoneal dialysis have higher levels of CD36 than monocytes from patients with CKD who are not on dialysis or individuals without renal disease. 77, 78 increased expression of sra has also been documented in macro phages from patients on hemodialysis. 83, 87, 88 uremic serum enhanced sra expression and activity in the human monocytic cell line u937. 83, 87, 88 such changes predict increased lipid uptake, inflammation, migration and trapping of macrophages. 75, 76, [79] [80] [81] 
-/-mice show a massive accumulation of cellular cholesterol that is independent of plasma cholesterol levels. 91 these find ings complement clinical observations demonstrating that the development of atherosclerotic complications in CKD does not necessarily follow plasma lipid levels and emphasize the importance of altered local dynamics in macrophage lipid handling under conditions of impaired renal function.
the key pathways for the movement of cholesterol out of macrophages involve an energydependent efflux that involves the cholesterol transporters aBCa1 and aBCG1, and the scavenger receptor srBi, which is driven by the cholesterol gradient (Figure 2 ). using the Apoe -/-mouse model, we showed that uni nephrectomy downregulates the expression of both macrophage Abca1 and the protein it encodes, but does not have signifi cant effects on abcg1 or srb1 expression. 91 notably, the repression of abca1 in macrophages of uni nephrectomized mice occurred despite very high levels of cellular cholesterol, the physio logical stimulus that increases cholesterol efflux via membrane transporters. interestingly, uremic plasma downregulates levels of aBCa1 in cultured human coronary artery endothelial cells. 92 Downregulation of aBCa1 expression in experi mental and human CKD might be caused by activation of the nuclear factor κB (nFκB) signaling pathway. [93] [94] [95] in support of this hypothesis, we showed that specific antag onism of nFκB activation pathways in macrophages of uninephrectomized Apoe -/-mice restored abca1 levels. 91 modulation of atPbinding cassette trans porters has also been reported for other chronic diseases, particularly diabetes mellitus, in which metabolic factors including reactive carbonyls and free fatty acids impair abca1 dependent cholesterol export by destabilizing abca1. 96, 97 these metabolites are also elevated in patients with CKD. 98 these findings indicate that repression of aBCa1 owing to renal dysfunction might contribute to the impaired clearance of excess cholesterol from arterial macrophages and suggest a potential target for interven tion in CKDinduced atherosclerosis. of note, treatment LXR/RXR, liver X receptor and retinoid X receptor heterodimer; mLDL, modified lowdensity lipoprotein; NFκB, nuclear factor κB; PPAR, peroxisome proliferatoractivated receptor; SR-A, scavenger receptor class A member 1; SRBI, scavenger receptor class B member I; VLDL, very-low-density lipoprotein.
reViewS with human aPoai did not reduce the athero sclerotic burden of nephrectomized Apoe -/-mice. 99 However, this intervention did lessen the lipid and collagen content of the atherosclerotic plaques and increased the area occupied by smooth muscle cells-changes that could be indicative of plaque stabilization. 99 in addition to modulating cholesterol homeostasis, aBCa1 has major antiinflammatory and anti apoptotic functions. 90 macrophages from abca1deficient mice have increased tolllike receptor (tlr) signaling, which enhances their inflammatory response to lipopoly saccharide and other tlr ligands.
100,101 upregulation of tlr2 and tlr4 has been reported in monocytes of dialysis patients with systemic inflammation, 102 whereas expression of these receptors was reportedly decreased in dialysis patients with low levels of Creactive protein. 103 aBCa1 also directly suppresses lipopolysaccharide induced inflammatory cytokine production by macro phages through a pathway that involves signal transducer and activator of transcription 3 and is independent of cholesterol export. 96 in view of the chronic systemic and vascular inflammation that prevails in CKD, repressed aBCa1 function in macrophages might be especially detrimental through suppression of lipid export and activation of the inflammatory response.
CKD and lipoproteins
CKD influences lipoproteins that are involved in macro phage function. CKD generates both atherogenic lDl and dysfunctional HDl particles. Plasma levels of modified and oxidized lDl, which correlate with cardio vascular event rates in the general population, 104 are elevated at all stages of CKD. 105 myeloperoxidasegenerated reactive nitrogen species facilitate lipid peroxidation and protein nitration, which enables lDl to be avidly taken up by CD36. 55, 106 Furthermore, the catalysis of lDl carbamyla tion by myeloperoxidase reduces the affinity of lDl for the lDl receptor and increases its affinity for scavenger receptors. 55, 107 such findings suggest that CKD might be associated with modifications in the composition and function of lDl that promotes atherosclerosis, but is not affected by lipidlowering therapy. 108, 109 CKD also affects HDl levels and function. low levels of HDl cholesterol are a powerful negative risk factor for cardiovascular disease, prevail at all stages of CKD and, as in the general population, are associated with increased mortality. 110 experimental and clinical studies demonstrate that several factors contribute to the low level of HDl in CKD, including reduced levels of aPoai, enriched levels of serum amyloid a, and decreased lecithin-cholesterol acyltransferase function. 84, 85, [110] [111] [112] CKD also impairs HDl maturation, which can pro foundly compromise many of its protective functions. For example, under normal conditions HDl fractions contain antioxidant enzymes such as paraxonase and gluta thione peroxidase. 113, 114 However, the accumula tion of advanced glycation end products and acrolein in CKD reduces the levels of these enzymes, compromising HDl function. indeed, HDl from patients with esrD has markedly reduced antioxidant and anti inflammatory activity, which is not altered by dialysis. 85, 112, [115] [116] [117] [118] Furthermore, HDl from patients on hemodialysis does not protect lDl from oxidation, 118 whereas the addi tion of an aPoai mimetic peptide to lDl obtained from patients on dialysis reduces its capacity to increase monocyte chemotactic activity in cultured endothelial cells. 118 taken together, these observations suggest that severe CKD influences the composition and function of lDl and HDl, as well as macrophage gene expression, to cause perturbations that are not necessarily targeted by current lipidlowering interventions. whether extreme reductions in lDl level have cardiovascular benefits in patients with esrD remains unknown, but the answer to this question might come from studying the direct cellular effects of statin therapy. statins suppress chole sterol synthesis and reduce intracellular concentrations of oxysterols and isoprenoids, inter mediaries that influ ence nuclear receptors and G proteins to modulate sig naling pathways and gene expression. the effect of statins on these pathways is influenced by cholesterol content and by cellular activation and differentiation. [119] [120] [121] [122] [123] [124] [125] For example, the downregulation of aBCa1 level induced by statins is more pronounced with increased macrophage differ entiation and less pronounced with increased chole sterol loading of the cell. 119 it is therefore possible that the activated macrophages of patients with advanced CKD do not respond normally to statin stimulation owing to their abnormal content and distribution of cell ular lipids.
CKD activation of angiotensin II
CKD activates the renin-angiotensin system (ras), which leads to heightening of its principal effec tor peptide, angiotensin ii, and ultimately modula tion of macrophage function. antagonism of the ras by angiotensin convertingenzyme (aCe) inhibitors or angiotensiniireceptor blockers (arBs) is the corner stone of treatment of progressive renal failure. 126, 127 angiotensin ii is also a major driving force in athero sclerosis. numerous epi demiological studies document fewer cardiovascular events and increased survival in individuals treated with antagonists or inhibitors of angiotensin ii. 128, 129 notably, these benefits are indepen dent of hemodynamic effects and underscore a more direct role for angiotensin ii in cardiovascular and renal diseases. the levels, duration, and localization of angiotensin ii activation that are neces sary to activate these disease pathways are unknown. activated angio tensin ii in CKD can potentiate macrophage infiltra tion of the arterial intima in every stage of atherogenesis. experimentally, a sustained increase in circulating levels of angiotensin ii through exogenous infusion causes recruitment of macro phages along with vascular inflamma tion, lesional neovascularization, hemorrhage and elastolysis in hyperlipidemic mice and rabbits. [130] [131] [132] [133] [134] [135] in clinical settings, shortterm elevations in angio tensin ii activity, such as hypotension, volume depletion, and cardiac ischemia, might have delayed consequences on atherosclerosis. we examined whether transient elevations in levels of angiotensin ii can affect future reViewS plaque development, and found that athero sclerosis was dramati cally increased in Apoeknockout mice 3 months after a 2week infusion of a non hypertensive dose of angiotensin ii. 130 as the amplifica tion of athero sclerosis did not occur during angiotensin ii infusion, these results confirm that angiotensin ii activates mecha nisms that promote and amplify atherogenic processes. indeed, angiotensin ii exposure caused an immediate increase in the vascular messenger rna expression of several chemoattractants (including CCl2 and its recep tor CCr2) and a subsequent accumula tion of macro phages in the aorta of angiotensiniiinfused mice. 130 interestingly, our ex vivo study found that macrophages harvested from angiotensiniiinfused mice had sub stantially increased migration across the cell mem brane in response to CCl2 chemotaxis. 136 moreover, angiotensin ii amplifies atherosclerosis and increases macrophage content in the aorta of mice carrying Apoe -/-macrophages. 136 Conversely, inhibition of angiotensin ii reduces macrophage infiltration and promotes compo sitional changes such as increased collagen content that might stabilize the atherosclerotic plaque. 137, 138 the modulation of macrophagespecific functions by angiotensin ii is supported by observations that mono cytes and macrophages express all components of the ras, including type1 (at 1 ) and type2 (at 2 ) angio tensin ii receptors. [139] [140] [141] In vitro, angiotensin ii increases the macrophagemediated modification and uptake of lDl, cholesterol synthesis in macrophages, differentiation of monocytes to macrophages, activation of macrophage generated oxidative stress, and levels of proinflammatory cytokines. 142 monocytes from patients with hypertension have high numbers of at 1 receptor in dimer form, which correlates with increased angiotensiniidependent adhesion to endothelial cells. 143, 144 the functional importance of the macrophage at 1 receptor in modulating atherosclerosis in vivo is illustrated by studies using chimeric mice in which the at 1 recep tor (atgr1) is either ablated or expressed exclusively in hematopoietic cells. [145] [146] [147] [148] transplantation of bone marrow from Atgr1knockout mice into athero sclerosisprone mice lacking either apoe or the lDl receptor did not markedly alter their atherosclerotic lesions.
145,147 infusion of angiotensin ii increased athero sclerosis and macro phage infiltration in Apoe -/-mice that had received bone marrow from Atgr1 +/+ mice but not in Apoe -/-mice that had received bone marrow from Atgr1knockout mice. likewise, reconstitution of Ldlrknockout mice with bone marrow from Atgr1 +/+ mice or Atgr1knockout mice pro duced the same results. 145, 147 By contrast, Atgr1knockout mice reconstituted with bone marrow from Atgr +/+ mice had increased atherosclerosis and decreased collagen content after exposure to angiotensin ii, consistent with the phenotype of a more unstable lesion. these findings suggest that in an angiotensinii heightened state, such as CKD, the macrophage at 1 receptor is responsible for acceleration and destabilization of plaques. 35 in this way, increased expression of aCe by circulating monocytes correlates with cardiovascular events and mortality in patients on hemodialysis. 149 inhibition of the action of angiotensin ii with aCe inhibitors or arBs reduces the risk of cardio vascular events in individuals with normal renal function. experimental findings suggest similar benefits in patients with CKD. we showed that atherosclerosis after uni nephrectomy in Apoe -/-mice is dramatically lessened by antagonism of angiotensin ii with losartan but not with the nonspecific antihypertensive agent, hydralazine. 35 the reduction in the atherosclerotic burden with losartan treatment was accompanied by changes in plaque com position that included fewer macrophages. moreover, in vitro macrophage migration was reduced by arB treatment. these effects on macrophage infiltration were accompanied by the preservation of extracellular matrix components, especially elastin, and decreased levels of the proteolytic enzyme, cathepsin s. none of these bene fits were observed in hydralazinetreated mice.
as discussed above, a reduction in renal mass by uninephrectomy decreases cholesterol efflux in macro phages via repression of the macrophage aBCa1 transporter. 91 In vivo treatment with an arB restored macrophage abca1 expression in the macrophages of uni nephrectomized Apoe -/-mice. these results comple ment previous in vivo and in vitro findings demon strating that exogenous angiotensin ii downregulates aBCa1. 150, 151 Furthermore, incubation of human and mouse macrophages with arBs, especially, telmisartan, increased cholesterol efflux via a peroxisome proliferator activated receptor γdependent pathway, which caused an upregulation of aBCa1 level. [150] [151] [152] [153] taken together, these observations suggest a pivotal importance of angiotensin ii-aBCa1 interaction for cholesterol homeo stasis in macrophages in the setting of renal dys function, which provides a basis for possible modulation of excess risk of cardiovascular disease in patients with CKD. interestingly, in vivo treatment of Apoe -/-mice with the arB losartan substantially attenuated upregula tion of nFκB subfamily proteins rela and p50, suggest ing a potential key regulatory step in this pathway in chole sterol efflux. 91 arB treatment was also found to have suppressive effects on nFκB in other tissues. 95, 154 CKDinduced activation of angiotensin ii can also derange lipoprotein composition and function. angiotensin ii promotes lDl oxidation and impairs maturation of HDl, whereas inhibition of angiotensin ii action has opposite effects. 138, 142, [153] [154] [155] [156] indeed, aCe inhibitors substantially reduced lipid myeloperoxidase mediated oxidation of lDl, 157 oxidizedlDlmediated transformation of cultured macrophages into foam cells, 158 and levels of oxidized lipoproteins in the serum and arteries of hypercholesterolemic rabbits and mice. 159 although experimental findings suggest that antag onism of angiotensin ii might benefit patients with CKD, clini cal studies remain sparse. Post hoc analysis of aCe inhibitor treatment in patients with mild to moderate renal impairment found an increased reduction in risk of cardiovascular events in these individuals than in those without compromised renal function. 2, 160 However, an inclusive evaluation of studies of aCe inhibitor or arB treatment on cardiovascular outcomes in patients with reViewS CKD, including esrD, did not allow a clear and defini tive interpretation of the findings. some studies did not find a benefit of angiotensin ii inhibition, [161] [162] [163] while many others, including a large metaanalysis, 164 report that patients with advanced CKD treated with aCe inhibitors or arBs have fewer cardiovascular events and reduced mortality. [165] [166] [167] [168] [169] [170] [171] Conclusions CKD affects macrophage function both directly and indirectly. Direct effects include upregulation of scav enger receptors, decreased cholesterol efflux via activa tion of nFκB and repression of aBCa1. indirect effects include the modification of lipoproteins that renders these particles more susceptible to scavenging by macro phages and inflammatory and oxidative insults to the endothelium that cause increased recruitment, trapping and decreased egress of arterial macrophages. many of these macrophage changes are linked to the activation of the ras and are responsive to treatment with agents that reduce vascular exposure to angiotensin ii. interventions that modulate macrophage behavior via antagonism of angiotensin might produce vascular bene fits across the spectrum of CKD.
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